Home Reimbursed medicines Adalimumab
Adalimumab — maximum prices and reimbursement
The CANAMED catalogue contains 55 medicines with the active substance Adalimumab, from 9 manufacturers. Below you can see each entry with the brand name, the manufacturer, the maximum retail price, the reimbursement percentage and the prescription status — plus live pharmacy prices, where we track them.
In short: for the active substance Adalimumab there are 55 authorised medicines in the CANAMED catalogue, with maximum retail prices between 913.60 and 2729.55 RON, from 9 manufacturers. For 19 of them the catalogue also records the reimbursement percentage. The maximum price is the legal cap — pharmacies may sell below it, so it is worth comparing the real price before you go. Latest import: 2026-11-03.
Data verified on from public sources (OpenStreetMap, chain websites, ANM/MS) — updated daily.
CANAMED catalogue
All medicines with Adalimumab
Maximum retail price = the legal selling cap. Sorted by price, lowest first.
| Brand name | Manufacturer | Maximum price | Reimbursement | Prescription |
|---|---|---|---|---|
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | 913.60 RON | not reimbursed | PR |
| HUMIRA 20mg/0,2ml | ABBVIE BIOTECHNOLOGY GMBH - GERMANIA | 1066.23 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1066.23 RON; you ~0.00 RON* |
PR |
| HYRIMOZ 40 mg/0,4 ml | SANDOZ GMBH - AUSTRIA | 1122.11 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1122.11 RON; you ~0.00 RON* |
PR |
| HULIO 40 mg | MCDERMOTT LABORATORIES T/A MYLAN DUBLIN BIOLOGICS - IRLANDA | 1184.91 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1184.91 RON; you ~0.00 RON* |
PR |
| HULIO 40 mg | MCDERMOTT LABORATORIES T/A MYLAN DUBLIN BIOLOGICS - IRLANDA | 1184.91 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1184.91 RON; you ~0.00 RON* |
PR |
| HUKYNDRA 40mg/0,4ml | IVERS-LEE CSM - GERMANIA | 1318.85 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1318.85 RON; you ~0.00 RON* |
PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | 1349.74 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~3.21 RON* |
PR |
| HUKYNDRA 80mg/0,8ml | IVERS-LEE CSM - GERMANIA | 1372.81 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1372.81 RON; you ~0.00 RON* |
PR |
| HYRIMOZ 40 mg/0,4 ml | SANDOZ GMBH - AUSTRIA | 1566.14 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~219.61 RON* |
PR |
| AMSPARITY 40mg/0,8ml | PFIZER SERVICE COMPANY BVBA - BELGIA | 1662.58 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~316.05 RON* |
PR _X0002_ |
| HYRIMOZ 40mg/0,8ml | SANDOZ GMBH - AUSTRIA | 1726.04 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~379.51 RON* |
PR |
| HUKYNDRA 80mg/0,8ml | IVERS-LEE CSM - GERMANIA | 1782.36 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1647.37 RON; you ~134.99 RON* |
PR |
| AMSPARITY 40mg/0,8ml | PFIZER SERVICE COMPANY BVBA - BELGIA | 1878.50 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~531.97 RON* |
PR |
| IMRALDI 40mg/0,8ml | BIOGEN (DENMARK) MANUFACTURING APS - DANEMARCA | 1992.33 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~645.80 RON* |
PR |
| IMRALDI 40mg/0,8ml | BIOGEN (DENMARK) MANUFACTURING APS - DANEMARCA | 1992.33 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~645.80 RON* |
PR |
| AMGEVITA 40 mg/0,4 ml | AMGEN EUROPE B.V. - OLANDA | 2100.18 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~753.65 RON* |
PR |
| HUMIRA 40mg/0,4ml | ABBVIE BIOTECHNOLOGY GMBH - GERMANIA | 2100.48 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~753.95 RON* |
PR |
| AMGEVITA 40mg/0,8ml | AMGEN EUROPE B.V. - OLANDA | 2102.00 RON | not reimbursed | PR |
| HEFIYA 40mg/0,8ml | SANDOZ GMBH - AUSTRIA | 2164.49 RON | not reimbursed | PR |
| YUFLYMA 80mg/0,8ml | MILLMOUNT HEALTHCARE LTD. - IRLANDA | 2329.22 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1647.37 RON; you ~681.85 RON* |
PR _X0002_ |
| HUMIRA 40mg/0,4ml | ABBVIE BIOTECHNOLOGY GMBH - GERMANIA | 2330.00 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1346.53 RON; you ~983.47 RON* |
PR |
| HUMIRA 80mg/0,8ml | ABBVIE BIOTECHNOLOGY GMBH - GERMANIA | 2729.55 RON | 100% · C1 (certain chronic diseases) CNAS pays ~1647.37 RON; you ~1082.18 RON* |
PR |
| AMGEVITA 40 mg/0,4 ml | AMGEN EUROPE B.V. - OLANDA | — | not reimbursed | PR |
| AMSPARITY 20mg/0,4ml | PFIZER SERVICE COMPANY BVBA - BELGIA | — | not reimbursed | PR _X0002_ |
| AMSPARITY 40 mg/0,8 ml | PFIZER SERVICE COMPANY BVBA - BELGIA | — | not reimbursed | PR _X0002_ |
| AMSPARITY 40mg/0,8ml | PFIZER SERVICE COMPANY BVBA - BELGIA | — | not reimbursed | PR _X0002_ |
| AMSPARITY 40mg/0,8ml | PFIZER SERVICE COMPANY BVBA - BELGIA | — | not reimbursed | PR _X0002_ |
| AMSPARITY 40mg/0,8ml | PFIZER SERVICE COMPANY BVBA - BELGIA | — | not reimbursed | PR _X0002_ |
| AMSPARITY 40mg/0,8ml | PFIZER SERVICE COMPANY BVBA - BELGIA | — | not reimbursed | PR _X0002_ |
| AMSPARITY 40mg/0,8ml | PFIZER SERVICE COMPANY BVBA - BELGIA | — | not reimbursed | PR |
| AMSPARITY 40mg/0,8ml | PFIZER SERVICE COMPANY BVBA - BELGIA | — | not reimbursed | PR |
| HUKYNDRA 40mg/0,4ml | IVERS-LEE CSM - GERMANIA | — | not reimbursed | PR |
| HUKYNDRA 40mg/0,4ml | IVERS-LEE CSM - GERMANIA | — | not reimbursed | PR |
| HUKYNDRA 40mg/0,4ml | IVERS-LEE CSM - GERMANIA | — | not reimbursed | PR |
| HUKYNDRA 40mg/0,4ml | IVERS-LEE CSM - GERMANIA | — | not reimbursed | PR |
| HUKYNDRA 40mg/0,4ml | IVERS-LEE CSM - GERMANIA | — | not reimbursed | PR |
| HULIO 20 mg | MCDERMOTT LABORATORIES T/A MYLAN DUBLIN BIOLOGICS - IRLANDA | — | not reimbursed | PR _X0002_ |
| HULIO 40 mg | MCDERMOTT LABORATORIES T/A MYLAN DUBLIN BIOLOGICS - IRLANDA | — | not reimbursed | PR _X0002_ |
| HULIO 40 mg | MCDERMOTT LABORATORIES T/A MYLAN DUBLIN BIOLOGICS - IRLANDA | — | not reimbursed | PR _X0002_ |
| HUMIRA 40mg/0,8ml | ABBVIE BIOTECHNOLOGY GMBH - GERMANIA | — | not reimbursed | PR |
| IMRALDI 40mg/0,4ml | BIOGEN (DENMARK) MANUFACTURING APS - DANEMARCA | — | not reimbursed | PR |
| IMRALDI 40mg/0,4ml | BIOGEN (DENMARK) MANUFACTURING APS - DANEMARCA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 40mg/0,4ml | MILLMOUNT HEALTHCARE LIMITED - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 80mg/0,8ml | MILLMOUNT HEALTHCARE LTD. - IRLANDA | — | not reimbursed | PR _X0002_ |
| YUFLYMA 80mg/0,8ml | MILLMOUNT HEALTHCARE LTD. - IRLANDA | — | not reimbursed | PR |
| YUFLYMA 80mg/0,8ml | MILLMOUNT HEALTHCARE LTD. - IRLANDA | — | not reimbursed | PR |
Reimbursement and amounts come from the CNAS nomenclature (SIUI) valid in the current month, for each pack. *What you pay is indicative: the maximum price minus what CNAS pays on the main sublist, for an insured adult. The pharmacy may sell below the maximum price; low-income pensioners, children, pupils and pregnant women may pay less. C1 applies only to the diseases on the list, and C2 within the national programmes.
Prescription status key:
- PR — With a medical prescription (PR)
- PR _X0002_ — With a medical prescription (PR _X0002_)
- PR _X0002_ — With a medical prescription (PR _X0002_)
Live pharmacy prices
Products with Adalimumab in our comparator
Shelf prices collected from the large chains — see on each product page where it is cheapest.
Good to know
How to read the maximum price
The CANAMED maximum retail price is the legal cap approved by the Ministry of Health — the pharmacy may sell for less, never for more. If the medicine is reimbursed, the sublist percentage (A 90%, B 50%, C1/C2 100%, D 20%) applies to the reference price of the therapeutic group, usually calculated from the cheapest product with the same INN — which is why your contribution can differ from one brand to another, even for the same active substance. The electronic prescription automatically shows the exact amount to pay; for non-prescription shelf prices, use the HartaFarmacii comparator.
CANAMED catalogue
Other active substances in the catalogue
- Apixaban
- Atorvastatin
- Atomoxetin
- Aripiprazol
- Abirateron
- Amoxicillin + acid clavulanic
- Allopurinol
- Amlodipin
- Aciclovir
- Acetylcystein
See also the full list of reimbursed medicines, with an alphabetical index of all active substances.
Frequently asked questions
FAQ · Adalimumab
-
Is Adalimumab reimbursed?
Yes. For 19 of the catalogue entries with Adalimumab we have the reimbursement percentage on record. The percentage depends on the CNAS sublist each product is placed on (A 90%, B 50%, C1/C2 100%, D 20%) and applies to the reference price of the therapeutic group, not to the shelf price. Ask the doctor or pharmacist for the exact placement. -
What is the CANAMED maximum price for Adalimumab?
The maximum retail prices (the CANAMED legal cap) for medicines with Adalimumab are between 913.60 and 2729.55 RON. No pharmacy may sell above the maximum price, but it may sell below it — compare real prices with the HartaFarmacii comparator. -
What percentage of Adalimumab is reimbursed?
The percentage depends on the CNAS sublist: A 90% (common chronic diseases), B 50% (partial reimbursement), C1 and C2 100% (serious chronic diseases and national programmes), D 20%. The percentage applies to the reference price set by CNAS, not to the shelf price, so you may pay a difference even for a “100% reimbursed” medicine. You can see the exact placement on the electronic prescription. -
How many medicines with Adalimumab are in the CANAMED catalogue?
The CANAMED catalogue holds 55 authorised medicines with the active substance Adalimumab — different brand names, strengths and pharmaceutical forms. You will find them all, with maximum price and prescription status, in the table on this page. Latest CANAMED import into the HartaFarmacii database: 2026-11-03.
Before you go